
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc focuses on developing innovative cell therapies for cancer treatment, with a promising pipeline that includes ITIL-306, which targets tumor-associated antigens across various solid tumors. The validation of the PD-(L)1 × VEGF activity, as seen in the recent reports, highlights the potential synergies within the therapeutic class and suggests a positive trajectory for the application of Instil Bio's TIL therapies. Furthermore, the potential for the CoStAR platform to expand into additional indications without being factored into current valuations indicates significant upside opportunities for the company's stock.
Bears say
Instil Bio's stock outlook is negatively impacted by the discontinuation of AXN-2510, which was deemed a core value driver, leading to a full thesis reset that emphasizes cash constraints. There are significant risks associated with the company’s clinical pipeline, including potential delays in advancing candidates and an inability to produce favorable clinical data, particularly concerning AXN-2510 in NSCLC and SCLC. Additionally, the termination of the collaboration agreement with ImmuneOnco Biopharmaceuticals raises further concerns about strategic direction, prompting a view of the stock as lacking immediate momentum and being valued close to cash levels.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares